-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 ISgvqgHWLw9GuT7kspHhac+6JzKWPcR/+98pGG88w4SKFA8EkVwo0GbqffCxTqXL
 qlN9zeZFpFdkQXIN35Eb4g==

<SEC-DOCUMENT>0001130319-08-000508.txt : 20080620
<SEC-HEADER>0001130319-08-000508.hdr.sgml : 20080620
<ACCEPTANCE-DATETIME>20080620141028
ACCESSION NUMBER:		0001130319-08-000508
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080620
FILED AS OF DATE:		20080620
DATE AS OF CHANGE:		20080620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CAMECO CORP
		CENTRAL INDEX KEY:			0001009001
		STANDARD INDUSTRIAL CLASSIFICATION:	MISCELLANEOUS METAL ORES [1090]
		IRS NUMBER:				980113090
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14228
		FILM NUMBER:		08909833

	BUSINESS ADDRESS:	
		STREET 1:		2121 11TH ST W
		CITY:			SASKATOON
		STATE:			A9
		ZIP:			S7M 1J3
		BUSINESS PHONE:		3069566200

	MAIL ADDRESS:	
		STREET 1:		2121 11TH ST W.
		CITY:			SASKATOON
		STATE:			A9
		ZIP:			S7M 1J3
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o41123e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Report of Foreign Private Issuer<BR>
Pursuant to Rule&nbsp;13a-16 or 15d-16 Under<BR>
the Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">For the month of June, 2008
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 15pt"><B>Cameco Corporation</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Commission file No.&nbsp;1-14228)</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 24pt"><B>2121-11th Street West<BR>
Saskatoon, Saskatchewan, Canada S7M 1J3</B><BR>
(Address of Principal Executive Offices)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 18pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F or Form 40-F.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the
Securities Exchange Act of 1934.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="right" valign="top"><DIV style="margin-left:0px; text-indent:-0px">Yes&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No&nbsp;&nbsp;&nbsp;<FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-2(b):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>Exhibit&nbsp;Index</B></U>
</DIV>

<DIV align="center" style="margin-top: 6pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="76%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Page No.</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">1.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated June&nbsp;20, 2008
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">3 &#150; 5</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 30pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B><BR>Cameco Corporation<BR></B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:&nbsp;&nbsp;June 20, 2008&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><I>&#147;O. Kim Goheen&#148;</I>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">O. Kim Goheen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Senior Vice-President and<BR>
Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>TSX:&nbsp;</B>CCO<BR>
<B>NYSE:&nbsp;</B>CCJ
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><IMG src="o41123o4112300.gif" alt="(CAMECO LOGO)">
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>website:&nbsp;</B>cameco.com<BR>
<B>currency:&nbsp;</B>Cdn</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 8pt; margin-top: 18pt">2121 &#150; 11<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Street West, Saskatoon, Saskatchewan, S7M 1J3 Canada<BR>
Tel: (306)&nbsp;956-6200&nbsp; &nbsp;Fax: (306)&nbsp;956-6201
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 24pt"><B>Cameco Joins GE Hitachi Enrichment Venture</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 18pt">Saskatoon, Saskatchewan, Canada, June&nbsp;20, 2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>Cameco Corporation </B>announced today it is joining a uranium enrichment business venture in the
United States, which will extend the company&#146;s involvement in the front end of the nuclear fuel
cycle beyond its current position as the world&#146;s largest uranium producer and a leading supplier of
uranium conversion services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Cameco has finalized an agreement with GE Hitachi Nuclear Energy (GEH)&nbsp;whereby a Cameco subsidiary
will provide $123.8&nbsp;million (US)&nbsp;to acquire a 24% interest in Global Laser Enrichment (GLE)&nbsp;based
in Wilmington, North Carolina. The remainder of GLE is owned indirectly by General Electric Company
(51%) and Hitachi Ltd. (25%). Cameco is utilizing its existing credit facilities to fund the
acquisition. At this time, Cameco does not expect to incur further development and
commercialization expenditures relating to GLE until 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">GLE is developing a third-generation uranium enrichment process using laser technology to
commercially enrich uranium for nuclear power plants. GLE is working on commercial facility
licensing activities to support its projected startup date of 2012 and expects to achieve
commercial production in 2013. GLE would be responsible for marketing all the enrichment services
from this plant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">&#147;This investment further expands and integrates Cameco&#146;s interests in the nuclear fuel cycle as we
pursue our objective to be a leading nuclear energy company, producing uranium fuel and generating
clean electricity,&#148; said Jerry Grandey, Cameco&#146;s president and CEO. &#147;It is fitting that three
leaders in the nuclear industry support the development of the next generation of uranium
enrichment technology.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Uranium enrichment is a key step in the process of producing fuel for light water nuclear power
plants. Cameco is currently involved in all steps of the nuclear fuel cycle leading up to uranium
enrichment, including the production of uranium hexafluoride (UF<SUB style="font-size: 85%; vertical-align: text-bottom">6</SUB>), which is the form of
uranium required for an enrichment plant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">In addition to the ownership of GLE, Cameco and GLE signed an agreement to pursue and collaborate
on complementary business opportunities in the front end of the nuclear fuel cycle.
Specifically, the parties may choose to market uranium and enrichment services together to satisfy
potential customer demand for bundled services.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are excited about the potential to collaborate more closely with GEH through participation in
GLE,&#148; Grandey added. &#147;Our businesses have potential synergies that can be explored to add value for
our shareholders.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">The demand for enriched uranium is projected to increase significantly in the next decade with the
anticipated construction of a new generation of nuclear power plants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">GLE has exclusive rights to develop, commercialize and launch the technology on a global basis
under a 2006 agreement with the original developer, the Australian company Silex Systems Ltd. The
next important milestone for the technology is the test loop phase, which is anticipated to begin
in late 2008. The test loop process is intended to verify performance and reliability data
necessary to support the construction of a commercial-scale enrichment facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 9pt">The target annual capacity of the proposed commercial facility is between 3.5 and 6&nbsp;million
separative work units (SWUs). GLE has selected Wilmington, North Carolina to host the potential
production facility. GE currently manufactures fuel bundles for light water nuclear power plants at
the site.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>Uranium Enrichment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Naturally occurring uranium is made up of two different isotopes, approximately 99.3% U-238 and
0.7% U-235. Uranium enrichment is the process that increases the U-235 concentration from 0.7%.
Most commercial reactors require uranium fuel to have a U-235 content
of 3 &#150; 5%. Enrichment
involves separation of the lighter U-235 atoms from the heavier and more predominant U-238 atoms in
order to concentrate the U-235 portion. There are currently two commercial enrichment methods:
gaseous diffusion and centrifuge.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>GE Hitachi Nuclear Energy</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Based in Wilmington, N.C., GEH is a world-leading provider of advanced reactors and nuclear
services. Established in June&nbsp;2007, GEH is a global nuclear alliance created by GE and Hitachi to
serve the global nuclear industry. The nuclear alliance executes a single, strategic vision to
create a broader portfolio of solutions, expanding its capabilities for new reactor and service
opportunities. The alliance offers customers around the world the technological leadership required
to effectively enhance reactor performance, power output and safety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>Hitachi</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Hitachi, Ltd., headquartered in Tokyo, Japan, is a leading global electronics company with
approximately 390,000 employees worldwide. Fiscal 2007 (ended March&nbsp;31, 2008) consolidated revenues
totalled 11,226&nbsp;billion yen ($112.2&nbsp;billion (US)). The company offers a wide range of systems,
products and services in market sectors including information systems, electronic
devices, power and industrial systems, consumer products, logistics, materials and financial
services.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Cameco Corporation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Cameco, with its head office in Saskatoon, Saskatchewan, is the world&#146;s largest uranium producer.
The company&#146;s uranium products are used to generate electricity in nuclear power plants around the
world, providing one of the cleanest sources of energy available today. Cameco&#146;s shares trade on
the Toronto and New York stock exchanges.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 15pt"><B>Caution Regarding Forward-Looking Information</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 9pt">Statements contained in this news release which are not current statements or historical facts are
forward-looking information or statements which may be material and that involve risks,
uncertainties and other factors that could cause actual results to differ materially from those
expressed or implied by them. Forward-looking information and statements are also based on a
number of assumptions which may prove to be incorrect. The statements above regarding the
expectation that no further development and commercialization expenditures relating to GLE will be
incurred by Cameco until 2010 assume that the funds available to GLE following the closing will be
sufficient to meet its anticipated expenditure budgets, and are subject to the risk that additional
funds will be required because planned expenses exceed budgeted levels, or unbudgeted expenses
arise. The statements above regarding the expected commencement of the test loop phase in late
2008, the projected startup date for a commercial facility in 2012, the expected commencement of
commercial production in 2013 and the target annual capacity of the commercial facility assume that
the test phase will commence and be completed as scheduled with favorable results demonstrating the
success and economic viability of the technology, that a decision to proceed to the development
stage is made, and that the steps necessary to achieve startup and commercial production can be
achieved within the expected timeframes. Those statements are subject to the risk that the
commencement or completion of the test loop phase is delayed, that the test results are
unfavourable, that no decision to proceed to the development stage is made or that unforeseen
difficulties with the technology or its ability to meet expected productivity levels at expected
cost levels occur.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">- End -
</DIV>

<DIV align="center" style="margin-top: 9pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Investor and media inquiries:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Alice Wong
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(306) 956-6337</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Investor inquiries:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Rachelle Girard
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(306) 956-6403</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Media inquiries:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Lyle Krahn
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(306) 956-6316</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o41123o4112300.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o41123o4112300.gif
M1TE&.#EA;P!,`*(``/___\S,S)F9F69F9C,S,P```````````"'Y!```````
M+`````!O`$P```/_"+K<_C#*-<*\..O-Y2B%U8UD:38?&)YLZSJ$JHIO;6^Q
MK`IW[S\YW>Q'O`6"0EYQZ0H(=\QH"ZDBT!A7J39"!0T<`4'LNRT[!$\R`RTC
MF-\`IU"M8`O=\&V7#K`_\7E,?B"`"BE/A'R!/D\HB`4#2HM+@P62?8@5DU)4
MA7))FU*5EUV%H3V7AX1K=V"JD)>G&@-TH`M=#4>/5K(:,9*?0PK!()?$B+&]
M0"`T@X6O!0V/0EG*#$$,KW14J=,ZIM9Q087<#-0+Q][)O<3D.C3'V=ZMX7'T
M"E3PW]?S0O7I[F3H:\.OGXQZ`$H5%&:/X"V#!Q%V6L@,W;Z'$$$@Q.>0_Z-`
MBSI8951D315%2^;>@82XKJ0*D55.TH&V:Z.C%77\+:ATI<N?:AL_`#LW;$X#
MGVV`VA2P34=3E3"-VHQPI1*6)]68$M@:2>G4!\>Z$?WJ8F)*6V195**3K@"!
MEFEQC,7TJ&O<$95,59)Z5^[%E6GZ=DBGB"9<P1+V*M(%!?$(FKQR#7CKN`1-
ME)5M((V<V<5E2%X[<_@<372+RZ%-;X"66O7JCZY??.`<+H!M,%$.+PHP^9L`
M"T=:QY97A587W<.+-EX3!/EP.[1O.G<=+/6OY!*:7W!"$CM=MQDF0[B]02EY
M"><GI*<*]%!W,+'$%,_Z`7@0-;RK`.4]KB53&?^:G($$`0$"`%L'8^14D3@R
M_.<4`#1E@<9;#D*22PQOA:$"'SG\EE\Q"ASH5S->H!,,91!6@=DG=$QX58G*
MM<A0#E5!$1$'GY`(7D$<KB)2(0M2\)(A&DFS(!N%S7`C!S3N-"1&L:00RR=.
MAF#;E8?P((<B:*C!T$I^"`<6%M@4%!^(+Y:6T#P\I)`:E<NX)2)>&#[IT9F8
MK;2`C]D5F9B="VE'@I3?'85FE5,^R2<704)@AZ,;QC08(2(\:F8#;"3JYY=Q
MZF8'4)_.B0%#ED*)Z:'*J;G<&6ON^``/=JS#AAN'@#,>D196J>:=I^:9*D:V
M8O)=>U]\8BNAP;SWD$=I,OK)JTB:JFD'ERA5YX@(AU23`V`%]JI$ML.4*4*'
M-_$!9XA5>"@?(*I$HE6>QGI+)H`>AM$;9W[TYAZ*&QKJJH(X-?2'OWREJD:F
@KR+E5C*J4'8??VVT.6"QVHC`6+H/O(*B9"HNO$`"`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
